Skip to content

Operating margin at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
26.4%+2.8pp
Amgen logo
AmgenAMGN
28.4%+6.6pp
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
-39,428.9%-49,795pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-697.7%+635pp
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-192.4%-205pp
TG Therapeutics logo
TG TherapeuticsTGTX
21.3%+5.9pp

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%
Enterprise value$3.88B+565%
P/S1,465.1×+962×

Profitability

See full
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Calculated from Dianthus Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Dianthus Therapeutics’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's operating margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dianthus Therapeutics's operating margin?
Dianthus Therapeutics (DNTH) reported operating margin of -4,558.4% in Q3 2025.
How has Dianthus Therapeutics's operating margin changed year-over-year?
Dianthus Therapeutics's operating margin decreased by 195.0% year-over-year, from -1,545% to -4,558.4%.
What does operating margin mean?
Operating income as a percentage of revenue (trailing twelve months). Captures profitability from core operations after both cost of revenue and operating expenses, but before interest and taxes.